HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $63.00 target price on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 255.73% from the stock's previous close.

ARCT has been the subject of a number of other research reports. BTIG Research began coverage on shares of Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $41.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $65.00.

Arcturus Therapeutics Trading Down 1.9 %

Shares of Arcturus Therapeutics stock traded down $0.34 during mid-day trading on Friday, reaching $17.71. 608,229 shares of the stock were exchanged, compared to its average volume of 421,925. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The company has a market cap of $479.76 million, a price-to-earnings ratio of -7.98 and a beta of 2.62. The firm has a 50-day simple moving average of $17.00 and a 200 day simple moving average of $18.89.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARCT. nVerses Capital LLC bought a new position in Arcturus Therapeutics in the 3rd quarter valued at $42,000. Virtus ETF Advisers LLC lifted its stake in shares of Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 1,132 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics during the fourth quarter valued at $71,000. National Bank of Canada FI increased its position in Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 4,784 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after purchasing an additional 2,038 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.